natgillin/translations-raw huggingface dataset:
Lenalidomide has been evaluated in two phase III studies in newly diagnosed multiple myeloma and two phase III studies in relapsed refractory multiple myeloma as described below.
Lenalidomid so ocenili v dveh študijah faze III pri novo diagnosticiranem diseminiranem plazmocitomu in v dveh študijah faze III pri ponovljenem, na zdravljenje neodzivnem diseminiranem plazmocitomu, kot je opisano v nadaljevanju.
Lenalidomide in combination with dexamethasone in patients who are not candidates for stem cell transplantation
Lenalidomid v kombinaciji z deksametazonom pri bolnikih, ki niso kandidati za presaditev matičnih celic
Lenalidomide in combination with melphalan and prednisone followed by maintenance monotherapy in patients who are not eligible for transplant
Lenalidomid v kombinaciji z melfalanom in prednizonom, ki jim sledi vzdrževalna monoterapija, pri bolnikih, ki niso primerni za presaditev
Lenalidomide induced in monkeys malformations similar to those described with thalidomide (see section 5.3).
Lenalidomid je povročil pri opicah deformacije, ki so podobne deformacijam opisanim pri talidomidu (glejte poglavje 5.3).
Lenalidomide induced in monkeys malformations similar to those described with thalidomide (see sections 4.6 and 5.3).
Lenalidomid je pri opicah povzročil deformacije, ki so podobne deformacijam, opisanim pri talidomidu (glejte poglavji 4.6 in 5.3).
Lenalidomide is associated with a higher incidence of grade 3 or 4 thrombocytopenia (37% in lenalidomide-treated patients compared with 1.5% in patients on placebo in the Phase III study).
Lenalidomid je povezan s povečano incidenco trombocitopenije 3. ali 4. stopnje (37 % pri bolnikih, ki so prejemali lenalidomid, v primerjavi z 1,5 % pri bolnikih, ki so prejemali placebo, v študiji faze III).
Lenalidomide is expected to be harmful for an unborn baby.
Za lenalidomid se pričakuje, da bo škodoval nerojenemu otroku.
Lenalidomide is expected to be harmful to an unborn child.
Pričakuje se, da je lenalidomid škodljiv za nerojenega otroka.
Lenalidomide is expected to be harmful to the unborn child.
Lenalidomid je lahko škodljiv za nerojene otroke.
Lenalidomide is expected to be harmful to the unborn child.
Pričakovati je, da lenalidomid škoduje nerojenemu otroku.
Lenalidomide is generally more soluble in organic solvents but exhibits the greatest solubility in 0.1N HCl buffer.
Lenalidomid je na splošno bolj topen v organskih topilih, vendar pa je najbolj topen v 0,1N HCl raztopini.
Lenalidomide is not recommended for the treatment of patients with high tumour burden if alternative treatment options are available.
Lenalidomida ne priporočajo za zdravljenje bolnikov z velikim tumorskim bremenom, če so na voljo druge možnosti zdravljenja.
Lenalidomide is present in the blood and sperm of patients receiving the medicine.
Pri bolnikih, ki se zdravijo z lenalidomidom, je le-ta prisoten v krvi in spermi.
Lenalidomide is substantially excreted by the kidney.
Lenalidomid se v glavnem izloča skozi ledvice.
Lenalidomide is substantially excreted by the kidney; patients with greater degrees of renal impairment can have impaired treatment tolerance (see section 4.4).
Lenalidomid se v glavnem izloča skozi ledvice; bolniki z višjimi stopnjami ledvične okvare lahko slabše prenašajo zdravljenje (glejte poglavje 4.4).
Lenalidomide may be continued in patients with Grade 1 or 2 tumour flare reaction (TFR) without interruption or modification, at the physician’s discretion.
Pri bolnikih z reakcijo izbruha tumorja (TFR - tumour flare reaction) 1. ali 2. stopnje lahko nadaljujete z lenalidomidom brez prekinitve ali prilagajanja, po presoji zdravnika.
Lenalidomide must be discontinued for angioedema, grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) is suspected, and should not be resumed following discontinuation from these reactions.
Lenalidomid morate ukiniti pri angioedemu, izpuščaju 4. stopnje, eksfoliativnem ali buloznem izpuščaju ali če posumite na Stevens-Johnsonov sindrom (SJS) ali toksično epidermalno nekrolizo (TEN - toxic epidermal necrolysis), in po ukinitvi zdravila zaradi teh reakcij se ne sme več začeti zdravljenja s tem zdravilom.
Lenalidomide must be discontinued for exfoliative or bullous rash, or if SJS or TEN is suspected, and should not be resumed following discontinuation for these reactions.
Lenalidomid je treba ukiniti pri eksfoliativnem ali buloznem izpuščaju ali če posumimo na SJS ali TEN in ga po ukinitvi zaradi teh reakcij ne smemo spet začeti dajati.
Lenalidomide treatment in mantle cell lymphoma patients is associated with a higher incidence of grade 3 and 4 neutropenia compared with patients on the control arm (see section 4.8).
Zdravljenje bolnikov z limfomom plaščnih celic z lenalidomidom je povezano z večjo incidenco nevtropenije 3. in 4. stopnje kot pri bolnikih v kontrolni skupini (glejte poglavje 4.8).
Lenalidomide treatment in myelodysplastic syndromes patients is associated with a higher incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to patients on placebo (see section 4.8).
Zdravljenje z lenalidomidom pri bolnikih z mielodisplastičnimi sindromomi je povezano z večjo pogostnostjo nevtropenije in trombocitopenije 3. in 4. stopnje kot pri bolnikih, ki prejemajo placebo (glejte poglavje 4.8).
Lenalidomide treatment must not be started if the Absolute Neutrophil Count (ANC) is < 1.0 x 109/L, and/or platelet counts are < 50 x 109/L.
Zdravljenja z lenalidomidom ne smete začeti, če je absolutno število nevtrofilcev (ANC – Absolute Neutrophil Count) < 1,0 x 109/l in/ali je število trombocitov < 50 x 109/l.
Lenalidomide treatment must not be started if the Absolute Neutrophil Count (ANC) is < 1.5 x 109/L, and/or platelet counts are < 75 x 109/L.
Zdravljenja z lenalidomidom ne smete začeti, če je absolutno število nevtrofilcev (ANC – Absolute Neutrophil Count) < 1,5 x 109/l in/ali je število trombocitov < 75 x 109/l.
Lenalidomide treatment must not be started if the ANC < 0.5 x 109/L and/or platelet counts < 25 x 109/L.
Zdravljenja z lenalidomidom ne smete začeti, če je ANC < 0,5 x 109/l in/ali število trombocitov < 25 x 109/l.
Lenalidomide treatment must not be started if the ANC < 1.0 x 109/L, and/or platelet counts < 75 x 109/L or, dependent on bone marrow infiltration by plasma cells, platelet counts < 30 x 109/L.
Zdravljenja z lenalidomidom ne smete začeti, če je ANC < 1,0 x 109/l in/ali število trombocitov < 75 x 109/l ali če je število trombocitov < 30 x 109/l, glede na infiltracijo plazmatk v kostni mozeg.
Lenalidomide treatment must not be started if the ANC is < 1.5 x 109/L, and/or platelet counts are
Zdravljenja z lenalidomidom ne smete začeti, če je ANC < 1,5 x 109/l in/ali je število trombocitov
Lenalidomide/ Dexamethasone N = 325
lenalidomid/ deksametazon N = 325
Length of follow-up
Trajanje spremljanja
Lennox-Gastaut syndrome is one of the most severe forms of epilepsy in children.
Lennox-Gastautov sindrom je ena izmed najtežjih oblik epilepsije pri otrocih.
Lennox-Gastaut syndrome is the name given to a group of severe epilepsies in which you may experience repeated seizures of various types.
Lennox- Gastautov sindrom je poimenovanje hude epilepsije, ko doživljate ponavljajoče se epileptične napade različnih vrst.
Lennox-Gastaut syndrome is the name given to a group of severe epilepsies in which you may experience repeated seizures of various types.
Lennox- Gastautov sindrom je poimenovanje skupine hude epilepsije, ko doživljate ponavljajoče se epileptične napade različnih vrst.
Lens opacities: following bexarotene treatment, some patients were observed to have previously undetected lens opacities or a change in pre-existing lens opacities unrelated to treatment duration or dose level of exposure.
Motnost očesne leče: Pri nekaterih bolnikih so po zdravljenju z beksarotenom opazili poprej neopažene motnosti očesne leče oz. spremembe že obstoječe motnosti očesne leče, ki pa niso bile povezane s trajanjem zdravljenja ali višino odmerka.
Lens opacity Visual impairment Vision blurred
Motnost leče Motnje vida Zamegljen vid
Lens subluxation was observed in 3 animal species at ocriplasmin concentrations above the intended clinical concentration (see section 5.3).
Subluksacijo leče so opazili pri 3 živalskih vrstah s koncentracijami okriplazmina nad predvidenimi kliničnimi koncentracijami (glejte poglavje 5.3).
Lens subluxation/phacodonesis
Subluksacija leče/fakodoneza
Lenvatinib exhibited good oral bioavailability in dogs (70.4%) and monkeys (78.4%).
Lenvatinib je pokazal dobro peroralno biološko uporabnost pri psih (70,4 %) in opicah (78,4 %).
Lenvatinib may adversely affect the wound healing process as other agents of the same class.
Lenvatinib, tako kot druga zdravila iste skupine, lahko neugodno vpliva na proces celjenja ran.
Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to < 480 ms or baseline.
Lenvatinib je treba spet začeti dajati v zmanjšanem odmerku, ko se podaljšanje intervala QTc vrne na < 480 ms ali izhodiščno vrednost.
Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to < 480 ms or baseline.
Lenvatinib je treba spet začeti dajati v zmanjšanem odmerku, ko se podaljšanje QTc vrne na < 480 ms ali izhodiščno vrednost.
Lenvatinib should be withheld in the event of development of QT interval prolongation greater than 500 ms.
Dajanje lenvatiniba je treba prekiniti, če se razvije podaljšanje intervala QT, ki presega 500 ms.
Lenvatinib should be withheld in the event of development of QT interval prolongation greater than 500 ms.
Lenvatiniba ne smemo dajati, če se razvije podaljšanje intervala QT, večje od 500 ms.
Lenvatinib showed minimal or no inhibitory activities toward P-gp-mediated and BCRP-mediated transport activities.
Lenvatinib je pokazal minimalno ali nikakršno inhibicijsko aktivnost proti prenašalskim aktivnostim, ki jih posredujeta P-gp in BCRP.
Lenvatinib showed minimal or no inhibitory effect on OATP1B3.
Lenvatinib je pokazal minimalen ali nikakršen inhibicijski učinek na OATP1B3.
LENVIMA 10 mg hard capsules lenvatinib
LENVIMA 10 mg trde kapsule lenvatinib
LENVIMA 10 mg hard capsules: - Each hard capsule contains 10 mg of lenvatinib (as mesilate).
LENVIMA 10 mg trde kapsule: - ena trda kapsula vsebuje 10 mg lenvatiniba (v obliki mesilata).
LENVIMA 4 mg hard capsules lenvatinib
LENVIMA 4 mg trde kapsule lenvatinib
LENVIMA 4 mg hard capsules LENVIMA 10 mg hard capsules
LENVIMA 4 mg trde kapsule LENVIMA 10 mg trde kapsule
LENVIMA 4 mg hard capsules: - Each hard capsule contains 4 mg of lenvatinib (as mesilate).
LENVIMA 4 mg trde kapsule: - ena trda kapsula vsebuje 4 mg lenvatiniba (v obliki mesilata);
Lenvima can only be obtained with a prescription and treatment must be started and supervised by a doctor who is experienced in using cancer medicines.
Izdaja zdravila Lenvima je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Lenvima contains the active substance lenvatinib.
Zdravilo Lenvima vsebuje zdravilno učinkovino lenvatinib.
Lenvima has been shown to be more effective than placebo (a dummy treatment) at slowing down disease progression in one main study.
Zdravilo Lenvima se je izkazalo za učinkovitejše od placeba (zdravila brez zdravilne učinkovine) pri upočasnitvi napredovanja bolezni v eni glavni študiji.
Lenvima is a cancer medicine used to treat adult patients with differentiated thyroid carcinoma, a type of cancer originating from the follicular cells of the thyroid gland.
Lenvima je zdravilo proti raku, ki se uporablja za zdravljenje odraslih bolnikov z diferenciranim karcinomom ščitnice, vrsto raka, ki nastane iz folikularnih celic ščitnice.
LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Zdravilo LENVIMA je indicirano za zdravljenje odraslih bolnikov s progresivnim, lokalno napredovalim ali metastatičnim, diferenciranim (papilarnim/folikularnim/Hürthle-celičnim) karcinomom ščitnice (DTC - differentiated thyroid carcinoma), odpornim proti radioaktivnemu jodu (RAI - refractory to radioactive iodine).
Lenvima is used when the cancer has progressed or spread locally or to other parts of the body, and does not respond to treatment with radioactive iodine.
Zdravilo Lenvima se uporablja, kadar rak napreduje ali se širi lokalno ali na druge dele telesa ter se ne odziva na zdravljenje z radioaktivnim jodom.
Leonardo Da Vincilaan 15 1831 Diegem
Omrix Biopharmaceuticals N. V. Leonardo Da Vincilaan 15
Lepirudin is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce lepirudin.
Lepirudin proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK) s katerim lahko tvori lepirudin.
Lepirudin was not mutagenic or clastogenic in standard assays for such effects.
Lepirudin ni bil mutagen ali klastogen v standardnih testih teh učinkov.
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR* titre ≥ 1:51/ml
Leptospira interrogans serološka skupina Australis serovar Bratislava, sev MSLB 1088 titer ALR* ≥ 1:51.
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR** titre ≥ 1:51
Leptospira interrogans serološka skupina Australis serovar Bratislava, sev MSLB 1088 titer ALR** ≥ 1:51
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR** titre ≥ 1:51.
Leptospira interrogans serološka skupina Australis serovar Bratislava, sev MSLB 1088 titer ALR** ≥ 1:51
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR** titre ≥ 1:51/ml
Leptospira interrogans serološka skupina Australis serovar Bratislava, sev MSLB 1088 titer ALR** ≥ 1:51/ml
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ARL* titre ≥ 1:51
Leptospira interrogans serološka skupina Australis serovar Bratislava, sev MSLB 1088 titer ALR* ≥ 1:51
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ARL** titre ≥ 1:51
Leptospira interrogans serološka skupina Australis serovar Bratislava, sev MSLB 1088 titer ALR** ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ALR* titre ≥ 1:51/ml
Leptospira interrogans serološka skupina Canicola serovar Canicola, sev MSLB 1090 titer ALR* ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ALR** titre ≥ 1:51
Leptospira interrogans serološka skupina Canicola serovar Canicola, sev MSLB 1090 titer ALR** ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ALR** titre ≥ 1:51/ml
Leptospira interrogans serološka skupina Canicola serovar Canicola, sev MSLB 1090 titer ALR** ≥ 1:51/ml
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ARL* titre ≥ 1:51
Leptospira interrogans serološka skupina Canicola serovar Canicola, sev MSLB 1090 titer ALR* ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ARL** titre ≥ 1:51
Leptospira interrogans serološka skupina Canicola serovar Canicola, sev MSLB 1090 titer ALR** ≥ 1:51
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ALR** titre ≥ 1:51
Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae, sev MSLB 1089 titer ALR** ≥ 1:51
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ARL* titre ≥ 1:51
Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae, sev MSLB 1089 titer ALR* ≥ 1:51
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ARL** titre ≥ 1:51
Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae, sev MSLB 1089 titer ALR** ≥ 1:51
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089 ALR** titre ≥ 1:51/ml
Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae, sev MSLB 1089 titer ALR** ≥ 1:51/ml
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ALR* titre ≥ 1:40/ml
Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, sev MSLB 1091 titer ALR* ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ALR** titre ≥ 1:40
Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, sev MSLB 109 titer ALR** ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ALR** titre ≥ 1:40
Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, sev MSLB 1091 titer ALR** ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ALR** titre ≥ 1:40/ml
Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, sev MSLB 1091 titer ALR** ≥ 1:40/ml
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ARL* titre ≥ 1:40
Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, sev MSLB 1091 titer ALR* ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ARL** titre ≥ 1:40
Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, sev MSLB 1091 titer ALR** ≥ 1:40
Leptospira:
Leptospiroza
leptospirosis, a bacterial disease that may be transmitted via infected urine and result in bleeding, hepatitis (inflammation of the liver) and jaundice or nephritis (kidney inflammation); rabies, a viral zoonotic (communicable to man) disease that affects the central nervous system (brain and spinal cord), leading to death.
leptospirozo, tj. bakterijsko boleznijo, ki se lahko prenaša z okuženim urinom in povzroči krvavitve, hepatitis (vnetje jeter) in zlatenico ali nefritis (vnetje ledvic); steklino, tj. virusno zoonozo (prenaša se lahko na ljudi), ki prizadene osrednje živčevje (možgane in hrbtenjačo) ter povzroči smrt.
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, France
Les Laboratoires Servier Industrie 905, route de Saran - 45520 Gidy, Francija
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co. Wicklow, Ireland
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, Francija Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co.
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road – Arklow – Co. Wicklow, Ireland
Les Laboratoires Servier Industrie, 905, route de Saran – 45520 Gidy, Francija Servier (Ireland) Industries Ltd, Gorey Road – Arklow – Co.
Lesinurad exposure is increased when it is co-administered with inhibitors of CYP2C9.
Med sočasno uporabo z zaviralci CYP2C9 se izpostavljenost lesinuradu poveča.
Lesinurad is a mild to moderate inducer of CYP3A and therefore may lower plasma concentrations of some hormonal contraceptives, thereby decreasing contraceptive effectiveness (see sections 4.4 and 4.6).
Lesinurad blago do zmerno inducira CYP3A in zato lahko zniža plazemsko koncentracijo nekaterih hormonskih kontraceptivov ter tako zmanjša njihovo kontracepcijsko učinkovitost (glejte poglavji 4.4 in 4.6).
Lesinurad is not an in vitro inhibitor of P-glycoprotein, BCRP, OATP1B3, MRP2, MRP4, OCT2, MATE1 and MATE2-K.
Lesinurad in vitro ne zavira P- glikoproteina, BCRP, OATP1B3, MRP2, MRP4, OCT2, MATE1 in MATE2-K.
Lesion Based Recurrence Rateb 12 months Mean (SD)
Stopnja ponovitve lezijb 12 mesecev Povprečje (SO)
lesion in intestine, abnormal opening between the wind pipe and the food pipe
razjeda na črevesju, nenormalna odprtina med sapnikom in požiralnikom
Lesion mean ratio
Povprečno razmerje lezij
Lesion mean ratio (95% CI)
(95-% IZ)
Lesion mean ratio (95% CI)
Povprečno razmerje
Lesion mean ratio (95% CI) P-value
povprečno razmerje lezij (95 % IZ) vrednost p
Lesion or condition if considered a significant risk factor for major bleeding.
Lezija ali bolezensko stanje, če le-ta predstavlja pomemben dejavnik tveganja za večje krvavitve.
lesions are not responding to systemic antiretroviral therapy, and radiotherapy or chemotherapy are not appropriate
če se lezije ne odzovejo na sistemsko antiretrovirusno terapijo, ter če radioterapija ali kemoterapija nista primerni
lesions are not ulcerated or lymphoedematous, and treatment of visceral KS is not required, and
lezije niso zagnojene in se niso razvili limfedemi, ter zdravljenje visceralnega KS ni potrebno, ter
lesions in the gums with an exposed jaw bone that does not heal and may be associated with pain and inflammation of the surrounding tissue (see the paragraphs below the list of side effects for further recommendations), hole in the gall bladder (symptoms and signs may include abdominal pain, fever, and nausea/vomiting).
lezije v dlesnih z izpostavljeno čeljustnico, ki se ne pozdravijo in so lahko povezane z bolečino in vnetjem okoliških tkiv (za nadaljnja priporočila glejte spodaj), luknja v žolčniku (simptomi in znaki lahko vključujejo bolečino v trebuhu, povišano telesno temperaturo in slabost/bruhanje).
less able to remember things existing neurological conditions may get worse
težave s pomnjenjem obstoječe nevrološke težave se lahko poslabšajo
Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell).
Manj pogosta, vendar resnejša neželena učinka, sta agranulocitoza (zelo nizka raven granulocitov, vrste belih krvničk) in nevtropenija (nizke ravni nevtrofilcev, vrste belih krvničk).
Less commonly, fever equal to or greater than 40 °C, tenderness at the injection site, prolonged inconsolable crying and redness and/or induration > 7 cm at the injection site or swelling of the entire limb have been reported.
Manj pogosto poročane reakcije so bile vročina  40 °C, občutljivost na mestu vbrizganja, trajajoč neutolažljiv jok in rdečina in/ali otrdlina > 7 cm na mestu vbrizganja ali otekanje celotnega uda.
Less exercise than usual.
Ste manj telesno dejavni kot ponavadi.
Less frequently reported, but more serious, adverse reactions include endophthalmitis, necrotizing retinitis, retinal detachment and retinal tear.
Resnejši neželeni učinki, o katerih poročajo redkeje, so: endoftalmitis, nekrotizirajoči retinitis, odstopanje očesne mrežnice in raztrganina mrežnice.
Less frequently reported, but more serious, adverse reactions include endophthalmitis, necrotizing retinitis, retinal detachment and retinal tear.
Resnejši neželeni učinki, o katerih so poročali redkeje, so: endoftalmitis, nekrotizirajoči retinitis, odstopanje očesne mrežnice in raztrganina mrežnice.
Less frequently reported, but more serious, adverse reactions include hypersensitivity reactions, eosinophilic pneumonia, drug rash with eosinophilia and systemic symptoms (DRESS), angioedema and rhabdomyolysis.
Med tistimi neželenimi učinki, o katerih so poročali manj pogosto, a so bolj resni, pa so preobčutljivostne reakcije, eozinofilna pljučnica, z zdravilom povezan izpuščaj z eozinofilijo in sistemskimi simptomi (sindrom DRESS), angioedem in rabdomioliza.
Less frequently reported:
Manj pogosto opisani:
Less frequently, decrease in serum calcium below normal range (hypocalcaemia) is reported.
Manj pogosto poročajo o znižanju serumskega kalcija pod spodnjo mejo normale (hipokalciemija).
Less frequently, some patients may experience pain at the infusion site, blisters, itching, sickness, tiredness, headache, breathing difficulties, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets.
Manj pogosto se lahko pri nekaterih bolnikih pojavijo bolečina na mestu infundiranja, mehurji, srbenje, slabost, utrujenost, glavobol, težave z dihanjem, otekanje jezika ali grla, srbeč ali smrkav nos, bruhanje, pordevanje ali hitro in močno utripanje srca, srčna kap ali nizko število trombocitov.
Less interest in sex
zmanjšanje spolne sle